Which adults with early breast cancer are eligible for abemaciclib (Verzenios) with endocrine therapy?

Abemaciclib (Verzenios) with endocrine therapy is indicated as adjuvant treatment for adults with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence; in pre- or perimenopausal women, aromatase inhibitor therapy should be combined with a luteinising hormone-releasing hormone agonist.